Pipeline

CARGO is advancing a pipeline
of transformational next-generation
CAR T-cell therapies for cancer

CARGO will be moving its Corporate Headquarters to 835 Industrial Road, Suite 400, San Carlos, CA 94070 on April 1, 2024

ProgramTarget(s)Indication(s)DiscoveryIND-enablingPhase 1Phase 2Phase 3Commercial rights
CRG-022 (CAR T) CD22 R/R LBCL - post CD19 CAR T
 
commercial rights logo
CRG-022 (CAR T) CD22 LBCL - CAR T naïve(1)
 
commercial rights logo
CRG-022 (CAR T) CD22 Pediatric B-ALL
 
commercial rights logo
CRG-023 (tri-specific CAR T with CD2 co-stimulation) CD19
CD20
CD22
B-cell malignancies
 
commercial rights logo
CRG-022 (CAR T)
DiscoveryIND-enablingPhase 1Phase 2Phase 3Commercial rights
Target: CD22
Indication: R/R LBCL - post CD19 CAR T
Target: CD22
Indication: LBCL - CAR T naïve(1)
Target: CD22
Indication: Pediatric B-ALL
CRG-023 (tri-specific CAR T with CD2 co-stimulation)
DiscoveryIND-enablingPhase 1Phase 2Phase 3Commercial rights
Target: CD19
CD20
CD22
Indication: B-cell malignancies

(1) Based on data from the Phase 1 clinical trial conducted by Stanford and pending data from our ongoing Phase 2 trial in R/R LBCL – post CD19 CaAR T, we intend to discuss with the FDA initiation of a Phase 2 program in LBCL – CAR T naïve without completing earlier clinical trials in LBCL – CAR T-naïve patients.